NASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis $14.30 -0.10 (-0.69%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$14.30 0.00 (-0.01%) As of 09/11/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RARE alerts:Sign Up Key Stats Today's Range$14.13▼$14.7050-Day Range$14.30▼$35.8752-Week Range$13.81▼$39.89Volume3.25 million shsAverage Volume4.35 million shsMarket Capitalization$1.41 billionP/E RatioN/ADividend YieldN/APrice Target$36.63Consensus RatingModerate Buy Company Overview Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options. Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia. The company also maintains a pipeline of investigational medicines, including gene therapies and other biologic treatments for rare diseases. Founded in 2010, Ultragenyx is headquartered in Novato, California, and serves patients through commercial operations and partnerships in the United States and international markets. The company was founded by Emil Kakkis, M.D., Ph.D., who continues to serve as its chief executive officer. Ultragenyx has also worked with other pharmaceutical companies to support the development, commercialization and distribution of its therapies.AI Generated. May Contain Errors. Read More Ultragenyx Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreRARE MarketRank™: Ultragenyx Pharmaceutical scored higher than 57% of companies evaluated by MarketBeat, and ranked 437th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.52, and is based on 1 strong buy rating, 10 buy ratings, 9 hold ratings, and 1 sell rating.Upside PotentialUltragenyx Pharmaceutical has a consensus price target of $36.63, representing about 156.2% upside from its current price of $14.30.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ultragenyx Pharmaceutical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($3.98) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ultragenyx Pharmaceutical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.34% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 7.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.13 News SentimentUltragenyx Pharmaceutical has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ultragenyx Pharmaceutical this week, compared to 11 articles on an average week.Search Interest31 people have searched for RARE on MarketBeat in the last 30 days. This is an increase of 3,000% compared to the previous 30 days.MarketBeat Follows16 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 1,500% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $99,106.00 in company stock.Percentage Held by Insiders5.20% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ultragenyx Pharmaceutical's insider trading history. Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RARE Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARESeptember 8, 2026 | globenewswire.comGoldman Sachs Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)September 7, 2026 | theglobeandmail.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | Investors Alley (Ad)Barclays Remains a Buy on Ultragenyx Pharmaceutical (RARE)September 7, 2026 | theglobeandmail.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $59.44 Consensus PT from AnalystsSeptember 6, 2026 | americanbankingnews.comBarclays Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock PriceSeptember 6, 2026 | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Cut to "Hold" at Royal Bank Of CanadaSeptember 6, 2026 | americanbankingnews.comThe Goldman Sachs Group Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $19.00September 6, 2026 | americanbankingnews.comSee More Headlines RARE Stock Analysis - Frequently Asked Questions How have RARE shares performed this year? Ultragenyx Pharmaceutical's stock was trading at $23.00 at the start of the year. Since then, RARE shares have decreased by 37.8% and is now trading at $14.30. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its quarterly earnings data on Tuesday, August, 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating analysts' consensus estimates of ($1.22) by $0.32. The company's revenue for the quarter was up 28.5% compared to the same quarter last year. Read the conference call transcript. When did Ultragenyx Pharmaceutical IPO? Ultragenyx Pharmaceutical (RARE) raised $112 million in an IPO on Friday, January 31st 2014. The company issued 5,760,369 shares at a price of $19.00-$20.00 per share. Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's top institutional investors include BlackRock Inc. (10.82%), California State Teachers Retirement System (3.44%), Wellington Management Group LLP (1.27%) and Bank of America Corp DE (1.16%). Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, Eric Crombez, John Richard Pinion, Howard Horn, Karah Herdman Parschauer, Erik Harris, Theodore Alan Huizenga, Shehnaaz Suliman, Corazon (Corsee) D Sanders and Matthew K Fust. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/04/2026Today9/12/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 10 days, RARE's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RARE CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,371Year Founded2010Price Target and Rating Average Price Target for Ultragenyx Pharmaceutical$36.63 High Price Target$90.00 Low Price Target$16.00 Potential Upside/Downside+156.2%Consensus RatingModerate Buy Rating Score (0-4)2.52 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($5.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$575 million Net Margins-81.79% Pretax Margin-81.18% Return on Equity-1,024.42% Return on Assets-44.40% Debt Debt-to-Equity RatioN/A Current Ratio1.73 Quick Ratio1.56 Sales & Book Value Annual Sales$673 million Price / Sales2.09 Cash FlowN/A Price / Cash FlowN/A Book Value($0.83) per share Price / Book-17.23Miscellaneous Outstanding Shares98,590,000Free Float93,462,000Market Cap$1.41 billion OptionableOptionable Beta0.31 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:RARE) was last updated on 9/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
